News

In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...
World leaders are dismantling global health programs and cutting back foreign aid. Will an extraordinary new medicine be able ...
The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...
Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...
The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...
National Aids Commission (NAC) and health campaigners have welcomed the approval of a twice-a-year HIV prevention injection ...
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.
While Gilead Sciences’ HIV prevention drug lenacapavir got approved by the US FDA, its made-in-India generic versions may be ...